Breast cancer screening in women age 40-49
A canadian study shows that screening programs for women in their 40s increase breast cancer net survival but not the rate of breast cancer diagnosis
Determinants of trastuzumab deruxtecan response in metastatic breast cancer
The phase 2 DAISY trial suggests that HER2 expression is determinant of trastuzumab deruxtecan efficacy, but additional mechanisms may be involved
A genomic assay for adjuvant chemotherapy choice in early breast cancer
Oncotype DX helps to decrease discordancy in adjuvant chemotherapy recommendations in early stage breast cancer
In early breast cancer a temporary interruption of endocrine therapy to attempt pregnancy is feasible
Among selected patients with previous hormone receptor–positive early breast cancer, temporary interruption of endocrine therapy to attempt pregnancy did not rise short-term risk of breast cancer events
Targeting an unexpected vulnerability p53-inactivated triple negative breast cancer
PROTAC, a new MDM2-targeted degrader, kills p53-inactivated triple negative breast cancer cells and suggests a new potential therapeutic target
Trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: results from DESTINY-Breast02
Compared with physician’s choice treatment, trastuzumab deruxtecan shows a favorable benefit-risk profile in patients with HER2+ metastatic breast cancer
A meta-analysis on anthracycline-taxane chemotherapy in early stage breast cancer
Anthracycline plus taxane regimens are among the most efficacious at reducing breast cancer recurrence and death, with optimal doses providing the greatest benefits
Atezolizumab and carboplatin in metastatic lobular breast cancer
The GELATO trial shows the feasibility of trials specifically designed for invasive lobular breast cancer and demonstrate antitumor activity of PD-L1 blockade and carboplatin
The role of pathologic complete response in early breast cancer after neoadjuvant therapy
Patients with HER2-positive early breast cancer who achieve a pathologic complete response have far better survival outcomes than patients who do not, but other prognostic factors count too
Prognostic value of ctDNA in triple-negative breast cancer
ctDNA and residual cancer burden after neoadjuvant systemic therapy are independently prognostic in triple-negative breast cancer patients